Day: January 15, 2023

Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) — Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers. The trial results are the first showing the potential of afamelanotide, a melanocortin drug under development by CLINUVEL, to protect and treat patients with xeroderma pigmentosum (XP), a rare disorder which causes extreme rates of skin cancers and forces patients to live in the dark. “XP patients are known as ‘children of the moon’ due to their need to avoid any light and sun exposure or risk severe, aggressive skin cancers from an early age,” CLINUVEL’s expert genomic scientist, Dr Jessica Nucci said. “Our first...

Expanded RFID capabilities in its store solution improves inventory accuracy, automates store processes and reduces labor costs NEW YORK, Jan. 15, 2023 (GLOBE NEWSWIRE) — Today at the NRF Big Show, Manhattan Associates Inc. (NASDAQ: MANH) unveiled its vision for an RFID-powered store. Manhattan Active® Omni suite has expanded its support of RFID tags for automating and streamlining the inventory counting, receiving, picking, checkout, return and exchange processes. With this new solution, retailers can make more accurate promises, increase conversion rates and maximize inventory exposure for selling. Retailers are increasingly depending on their stores to fulfill both in-store and online orders. However, their ability to do so is often hindered by poor store inventory accuracy, which often falls below 70%. In fact, a recent Manhattan...